White Paper
REMAINING PRAGMATIC WHILE MOVING UP THE VALUE CHAIN
This EVERSANA white paper analyzes the outlook for China’s healthcare industry in 2023, highlighting how post-pandemic reopening, an aging population, and healthcare reforms are driving demand while increasing pressure on healthcare resources and public funding. It explains that continued reimbursement reforms, price reductions, and value-based procurement will intensify competition for pharmaceutical and medical device companies. The paper discusses how multinational companies are responding through product diversification and localization, while domestic biotech firms are focusing on innovation, strategic partnerships, and overseas expansion amid funding challenges. It concludes that long-term success will depend on innovation, collaboration, localization, and adapting to China’s evolvin
